ADC Therapeutics SA (ADCT) SEC Filings & Earnings Calls

Preliminary financial results are unaudited and subject to material adjustments.

“The preliminary financial information is not a comprehensive statement... Subsequent information or events may lead to material differences” · word for word

Shareholder dilution from PIPE and warrant exercises.

“selling 12.9 million common shares at $1.42 per share and pre-funded warrants to purchase 48.1 million common shares” · word for word

Regulatory risk - potential withdrawal of accelerated approval

“The FDA noted substantial concerns regarding the benefit-risk or verification of clinical benefit observed in this trial based on the imbalance in Grade 5 events, when assessed in the context of a marginal treatment benefit.” · word for word

Clinical trial safety signal

“A higher rate of Grade 5 TEAEs was observed in the ZYNLONTA plus rituximab arm (27 pts/13.2%) vs. R-GemOx (9 pts/4.6%).” · word for word

Restructuring execution risk

“We are reducing our global workforce by approximately 17%, which is expected to be substantially completed by September 30, 2026.” · word for word

Revenue concentration on single product

“We generate product revenue through the sale of ZYNLONTA in the United States.” · word for word

FDA regulatory setback for LOTIS-5; potential delay or denial of full approval.

“FDA pre-sBLA meeting noted 'substantial concerns regarding the benefit-risk' and 'marginal treatment benefit'.”

Dependence on ZYNLONTA as sole commercial product; limited pipeline diversification.

“Net product revenue entirely from ZYNLONTA; LOTIS-7 and MZL IIT data pending.”

Restructuring execution risk; workforce reduction may impact morale and capabilities.

“17% workforce reduction; $10M annual savings target.”

Key person retention risk mitigated via awards; potential cash outflow if executives leave before June 2027.

“Cash portion subject to repayment if employment terminates before June 30, 2027.”

Execution risk on achieving cost savings; potential additional costs not currently contemplated.

“Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the reduction.” · word for word

Safety signal: higher Grade 5 TEAEs and SAEs in test arm, particularly in elderly patients.

“Higher rates of serious adverse events were seen in the test arm (49.0% vs. 34.5%). A higher rate of Grade 5 TEAEs was observed in the ZYNLONTA plus rituximab arm (27 pts/13.2%) vs. R-GemOx (9 pts/4.6%).”

Regulatory risk: sBLA submission and approval not guaranteed; FDA feedback pending.

“Company plans to conduct a pre-sBLA meeting with FDA in August and is preparing for a planned sBLA submission in Q4 2026.”

High debt and royalty obligation burden

“Deferred royalty obligation, long-term $304,687k and Senior secured term loans, long-term $111,042k”

Negative equity and accumulated deficit

“Total shareholders’ (deficit) equity $(216,377)k and Accumulated deficit $(1,668,909)k”

Dependence on single product ZYNLONTA

“The Company generates sales from its flagship product, ZYNLONTA” · word for word

Customer concentration risk

“AmerisourceBergen Corporation 39%, McKesson 36%, Cardinal Health 25% of product revenues”

Clinical trial risk: LOTIS-5 and LOTIS-7 data readouts are binary catalysts; failure could impair growth trajectory.

“LOTIS-5 Phase 3 topline data expected in second quarter 2026; full data for LOTIS-5 and LOTIS-7 anticipated by year end.” · word for word

Revenue concentration on ZYNLONTA; dependence on label expansion for growth.

“Net product revenues were $20.0 million; pipeline expansion needed for sustained growth.” · word for word

Restructuring costs of $13.1M in FY2025 related to strategic reprioritization.

“The Company incurred $0.3 million in income for the fourth quarter and $13.1 million in restructuring, impairment and other related costs for the full year ended December 31, 2025” · word for word

Single product dependency

“We generate product revenue through the sale of ZYNLONTA in the United States.” · word for word

Restructuring execution risk

“The Company closed down its UK facility, and has reduced its global workforce across functions by approximately 30%.” · word for word

Patent expiration risk

“Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar medications.” · word for word

Significant shareholder dilution from warrant issuance; potential further dilution if warrants are exercised.

“Issued warrants for 9.8M shares at $3.813, representing ~10% of current shares (assuming ~100M shares outstanding).”

Increased financial obligations post-change-of-control; royalty buyout amounts are substantial relative to company size.

“Royalty buyout of $525M-$750M, plus change-of-control payment, could exceed company's market cap.”

Preliminary and unaudited results; subject to change.

“The revenue and cash and cash equivalents figures are preliminary and unaudited.” · word for word

Clinical trial data is early-stage; safety includes Grade 5 AEs in 2 patients.

“Grade 5 AEs occurred in 2 (4.1%) patients.” · word for word

Revenue decline and continued net losses indicate commercial challenges.

“Net product revenue down 12% YoY; net loss of $41M.”

Dependence on clinical trial outcomes for future growth.

“LOTIS-5 topline results expected in 1H 2026; regulatory approval risk.”

Tariff cost pressure

“We operate internationally and our products are manufactured outside of the United States, primarily in Europe. As a result, we may experience higher costs of sales and increased operating expenses in the future due to tariffs that may be imposed on U.S imports of our product for commercial sale in the U.S.” · word for word

Drug pricing policy risk

“if MFN drug pricing is implemented, the U.S. list price of ZYNLONTA that is also being commercialized outside of the United States could be substantially reduced, which could negatively impact our U.S. product sale revenues and the overall U.S. market opportunity.” · word for word